Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia

Rajagopalan, Krithika; Trueman, David; Crowe, Lydia; Squirrell, Daniel; Loebel, Antony

doi:10.1007/s40273-016-0405-0

Cited by 11 publications

(49 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite being developed in the US [26], the Lenert classification may be generalisable to the European population [28]. Indeed, the Lenert classification of HS and the corresponding utility weights have been used in a number of pharmacoeconomic analyses in European and non-European countries [29–34]. The present study provides estimates of resource use associated with schizophrenia management for each of the eight Lenert HS.…”

Section: Introductionmentioning

confidence: 99%

Healthcare resource use in schizophrenia, EuroSC findings

Millier

Horváth

Kóczián

et al. 2017

Journal of Market Access & Health Policy

View full text Add to dashboard Cite

Background: It is unclear if the burden associated with schizophrenia is affected by the type and severity of patient’s symptoms. Objective: This study aims to quantify healthcare resource use associated with different profiles of schizophrenia symptoms. Study design: Post-hoc analysis of data from a naturalistic follow-up study. Setting: Secondary psychiatric services in France, Germany and the UK. Patients: EuroSC cohort:, representative sample of 1,208 schizophrenia patients Main outcome measure: We classified patients into eight health states, according to the Lenert classification (HS1–HS8), and estimated 6-month healthcare resource use (outpatient and day clinic visits, and hospitalisations) across the health states. Results: Approximately half of the patients were classed as having mild symptoms (HS1), with around 20% experiencing moderate, predominantly negative symptoms (HS2). The remaining health states were represented by <10% of patients each. Very few patients experienced extremely severe symptoms (HS8). No health state was associated with excess utilisation across all resource types. In terms of outpatient visits, patients were estimated to see a psychiatrist most often (3.01–4.15 visits over 6 months). Hospital admission was needed in 11%(HS1) – 35%(HS8) of patients and inpatient stays were generally prolonged for all health states (39–57 days). The average number of inpatient days was highest for patients in HS8 (18.17 days), followed by patients with severe negative symptoms (HS4; 13.37 days). In other health states characterised by severe symptoms (HS5–HS7), the average number of inpatient days was approximately half of those seen for HS4 (6.09–7.66). Conclusion: While none of the symptom profiles was associated with excess resource usage, hospitalization days were highest for HS with severe, predominantly negative or extremely severe symptoms. Patients with predominantly negative, moderate or severe symptoms appeared to have a high number of psychologist visits – an interesting finding that may reflect a specific therapeutic approach to the treatment of these patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Healthcare resource use in schizophrenia, EuroSC findings

Millier

Horváth

Kóczián

et al. 2017

Journal of Market Access & Health Policy

View full text Add to dashboard Cite

show abstract

“…The other 55 were excluded as they were not CUA, not using a utility weight for the health state of schizophrenia, or not reporting detailed utility values. The characteristics of the newly identified CUAs [23,24,[48][49][50] are presented in Supplement 1; the others can be found in the previous review [6]. The total CUAs included were conducted in 16 countries/regions (mostly in the USA, n = 8), with cohortlevel models (16 Markov models and 15 decision tree models).…”

Section: Resultsmentioning

confidence: 99%

“…Of them, most derived the utility values from published literatures, and 2 through interviews [42,43], and 1 through database analysis [29]. The other four studies [11,26,35,50] reported a systematic review process before the selection of the source, with 2 [26,35] identifying the utility elicitation studies through reviewing economic evaluations, and another 2 [11,50] through reviewing utility elicitation studies.…”

Section: Selection Of Source Of Utility Valuementioning

confidence: 99%

See 1 more Smart Citation

Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results

Zhou

Millier

François

et al. 2019

Journal of Market Access & Health Policy

View full text Add to dashboard Cite

Background and Objectives: Utility elicitation studies for schizophrenia generate different utility values for the same health states. We reviewed utility values used in schizophrenia pharmacoeconomic evaluations and evaluated the impact of their selection on the incremental costeffectiveness ratio (ICER). Methods: A systematic search was performed in Medline and Embase. Health state definitions, associated utility values, elicitation studies, and value selection processes were extracted. Sets of utility values for all schizophrenia health states were used in a cost-effectiveness model to evaluate the ICER. Results: Thirty-five cost-utility analyses (CUAs) referring to 11 utility elicitation studies were included. The most frequent health states were 'stable' (28 CUAs, 7 utility elicitation studies, 10 values, value range 0.650-0.919), 'relapse requiring hospitalisation' (18, 5, 7, 0.270-0.604), 'relapse not requiring hospitalisation' (18, 5, 10, 0.460-0.762), and 'relapse only' (10, 5, 6, 0.498-0.700). Seventeen sets of utility values were identified with difference in utility values between relapse and stable ranging from −0.358 to −0.050, resulting in ICERs ranging from −56.2% to +222.6% from average. Conclusion: The use of utility values for schizophrenia health states differs among CUAs and impacts on the ICER. More rigorous and transparent use of utility values and sensitivity analysis with different sets of utility values are suggested for future CUAs.

show abstract

“…The data on economic evaluation were extracted on a spreadsheet preformatted in Microsoft Excel® by two independent authors (ICBH and TML), and any disagreement was resolved by a third author (PMA). The following data were extracted type of economic evaluation, type of population, country, payer's perspectives, reference [14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30] which fully met the eligibility criteria were selected for this systematic review (Figure 1).…”

Section: Data Extractionmentioning

confidence: 99%

Economic evaluations on the use of aripiprazole for patients with schizophrenia: A systematic review

et al. 2019

View full text Add to dashboard Cite

What is known and objectives: Schizophrenia is a serious mental disorder and is associated with substantial economic and social burden. Cost-effectiveness analysis is important to assess the costs of different therapeutic options. However, there is a lack of information on the reporting quality of economic evaluations, cost drivers, as well as updated data focused on aripiprazole, an antipsychotic drug commonly prescribed in schizophrenia. This study evaluates and summarizes the evidence of economic evaluations of the use of aripiprazole in schizophrenia. In addition, we aimed to identify cost drivers and critically assess the reporting qualities of these studies. Methods: A comprehensive literature research was conducted using PubMed, NHS Economic Evaluation Database, CEA Registry and LILACS databases dated until March 2018. Full economic analyses of aripiprazole in schizophrenia that were based Identify the study as an economic evaluation or use more specific terms such as 'cost-effectiveness analysis', and describe the interventions compared 8 (47.0%

show abstract

Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia

Cited by 11 publications

References 41 publications

Healthcare resource use in schizophrenia, EuroSC findings

Healthcare resource use in schizophrenia, EuroSC findings

Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results

Economic evaluations on the use of aripiprazole for patients with schizophrenia: A systematic review

Contact Info

Product

Resources

About